Abstract
Dyspepsia refers to a heterogeneous group of symptoms that are localized in the epigastric region. Typical dyspeptic symptoms include postprandial fullness, early satiation, epigastric pain and epigastric burning, but other upper gastrointestinal symptoms such as nausea, belching or abdominal bloating often occur. Functional dyspepsia is defined as the presence of dyspeptic symptoms in the absence of an organic cause that readily explains them. The Rome III consensus proposed the subdivision of functional dyspepsia into postprandial distress syndrome (PDS), characterized by postprandial fullness and early satiation, and epigastric pain syndrome (EPS), characterized by epigastric pain or burning. Epidemiological studies in the USA and Europe confirmed the presence of both subgroups, with good separation between EPS and PDS. By contrast, other studies have found major overlap between EPS and PDS in patients with functional dyspepsia in specialist care centres in Europe and Asia. Preliminary pathophysiological studies suggest that PDS might be characterized by a higher prevalence of impaired gastric accommodation than EPS and raised duodenal eosinophil counts. Whether different treatment approaches are needed for EPS and PDS is currently unclear; only acotiamide, a new drug for the treatment of functional dyspepsia, has been found to be efficacious in PDS but not in EPS. Further randomized controlled trials testing treatment response by subgroup are urgently needed.
Key Points
-
Functional dyspepsia refers to dyspeptic symptoms that cannot currently be explained by an organic cause
-
The Rome III criteria has divided functional dyspepsia into two subgroups; postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS)
-
Patients with PDS typically report postprandial fullness and early satiation, whereas those with EPS are more likely to experience epigastric pain and burning
-
Currently, it is unknown whether patients with PDS and EPS need to be treated differently; randomized controlled trials are required to test treatment response by subgroup
Similar content being viewed by others
References
Tack, J. in Sleisenger and Fordtran, Handbook of Gastroenterology 9th edn, Vol. 1, Ch. 13 (eds Feldman, M., Friedman, L. S. & Brandt, L. J.) 183–196 (Saunders, Philadelphia, 2010).
Drossman, D. A. et al. Identification of subgroups of functional gastrointestinal disorders. Gastroenterol. Int. 3, 159–172 (1990).
Talley, N. J. et al. Functional gastroduodenal disorders. Gut 45 (Suppl. 2), 37–42 (1999).
Tack, J. et al. Functional gastroduodenal disorders. Gastroenterology 130, 1466–1479 (2006).
Nesland, A. & Berstad, A. Erosive prepyloric changes in persons with and without dyspepsia. Scand. J. Gastroenterol. 20, 222–228 (1985).
Talley, N. J. et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin. Gastroenterol. Hepatol. 5, 1175–1183 (2007).
Mazzoleni, L. E. et al. Helicobacter pylori eradication in functional dyspepsia: HEROES trial. Arch. Intern. Med. 171, 1929–1936 (2011).
Vanheel, H. & Farré, R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nat. Rev. Gastroenterol. Hepatol. http://dx.doi.org/10.1038/nrgastro.2012.255.
El-Serag, H. B. & Talley, N. J. Systematic review: the prevalence and clinical course of functional dyspepsia. Aliment. Pharmacol. Ther. 19, 643–654 (2004).
Piessevaux, H. et al. Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings. Neurogastroenterol. Motil. 21, 378–388 (2009).
Agreus, L. Natural history of dyspepsia. Gut 50 (Suppl. 4), iv2–iv9 (2002).
Camilleri, M. et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin. Gastroenterol. Hepatol. 3, 543–552 (2005).
Enck, P., Dubois, D. & Marquis, P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol. Suppl. 231, 48–54 (1999).
Moayyedi, P. & Mason, J. Clinical and economic consequences of dyspepsia in the community. Gut 50 (Suppl. 4), iv10–iv12 (2002).
Koloski, N. A., Talley, N. J. & Boyce, P. M. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. Am. J. Gastroenterol. 96, 1340–1349 (2001).
Tack, J., Bisschops, R. & Sarnelli, G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127, 1239–1255 (2004).
Jones, M. P., Talley, N. J., Eslick, G. D., Dubois, D. & Tack, J. Community subgroups in dyspepsia and their association with weight loss. Am. J. Gastroenterol. 103, 2051–2060 (2008).
Colin-Jones, D. G. et al. Management of dyspepsia. Report of a working party. Lancet 1, 576–579 (1988).
Locke, G. R. 3rd, Zinsmeister, A. R., Fett, S. L., Melton, L. J. 3rd & Talley, N. J. Overlap of gastrointestinal symptom complexes in a US community. Neurogastroenterol. Motil. 17, 29–34 (2005).
Carlsson, R. et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand. J. Gastroenterol. 33, 1023–1029 (1998).
Johnsson, F., Roth, Y., Damgaard Pedersen, N. E. & Joelsson, B. Cimetidine improves GERD symptoms in patients selected by a validated GERD questionnaire. Aliment. Pharmacol. Ther. 7, 81–86 (1993).
Tack, J. et al. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut 54, 1370–1376 (2005).
Corsetti, M., Caenepeel, P., Fischler, B., Janssens, J. & Tack, J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am. J. Gastroenterol. 99, 1152–1159 (2004).
Laheij, R. J. et al. Predominant symptom behavior in patients with persistent dyspepsia during treatment. J. Clin. Gastroenterol. 38, 490–495 (2004).
Talley, N. J. et al. Predictors of the placebo response in functional dyspepsia. Aliment. Pharmacol. Ther. 23, 923–936 (2006).
Karamanolis, G., Caenepeel, P., Arts, J. & Tack, J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 130, 296–303 (2006).
Castillo, E. J. et al. A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin. Gastroenterol. Hepatol. 2, 985–996 (2004).
Bisschops, R. et al. Relationship between symptoms and ingestion of a meal in functional dyspepsia. Gut 57, 1495–1503 (2008).
Choung, R. S., Locke, G. R., Schleck, C. D., Zinsmeister, A. R. & Talley, N. J. Do distinct dyspepsia subgroups exist in the community? A population-based study. Am. J. Gastroenterol. 102, 1983–1989 (2007).
Aro, P. et al. Anxiety is associated with uninvestigated and functional dyspepsia (ROME III criteria) in a Swedish population based study. Gastroenterology 137, 94–100 (2009).
Zagari, R. M. et al. Epidemiology of functional dyspepsia and subgroups in the Italian general population: an endoscopic study. Gastroenterology 138, 1302–1311 (2010).
Matsuzaki, J. et al. Classification of functional dyspepsia based on concomitant bowel symptoms. Neurogastroenterol. Motil. 24, 325–e164 (2012).
Matsuzaki, J. et al. High frequency of overlap between functional dyspepsia and overactive bladder. Neurogastroenterol. Motil. 24, 821–827 (2012).
van Kerkhoven, L. A. et al. Functional dyspepsia: not all roads seem to lead to Rome. J. Clin. Gastroenterol. 43, 118–122 (2009).
Wang, A. J. et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol. 8, 43 (2008).
Arts, J. et al. Discriminant value of dyspepsia subgroups according to the Rome III consensus in dyspeptic patients referred for upper gastrointestinal endoscopy [abstract]. Gastroenterology 134 (Suppl. 1), A-627 (2008).
Abid, S., Siddiqui, S. & Jafri, W. Discriminant value of Rome III questionnaire in dyspeptic patients. Saudi J. Gastroenterol. 17, 129–133 (2011).
Haag, S. et al. Is there any association between disturbed gastrointestinal visceromotor and sensory function and impaired quality of life in functional dyspepsia? Neurogastroenterol. Motil. 22, 262–e79 (2010).
Shindo, T. et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion 79, 65–72 (2009).
Kindt, S. et al. Impaired accommodation is a feature of functional dyspepsia patients with postprandial distress syndrome, not with epigastric pain syndrome [abstract]. Gastroenterology 136 (Suppl. 1), A-140–A-141 (2009).
Ahmed, A. B., Matre, K., Hausken, T., Gregersen, H. & Gilja, O. H. ROME III Subgroups of functional dyspepsia exhibit different characteristics of antral strain measured by strain rate imaging [abstract]. Gastroenterology 134 (Suppl. 1), A-531 (2008).
Kusano, M. et al. Rapid gastric emptying, rather than delayed gastric emptying, might provoke functional dyspepsia. J. Gastroenterol. Hepatol. 26 (Suppl. 3), 75–78 (2011).
Vilaichone, R. K., Mahacahai, V., Tumwasorn, S. & Kachintorn, U. CagA genotype and metronidazole resistant strain of Helicobacter pylori in functional dyspepsia in Thailand. J. Gastroenterol. Hepatol. 26 (Suppl. 3), 46–48 (2011).
Noh, Y. W., Jung, H. K., Kim, S. E. & Jung, S. A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J. Neurogastroenterol. Motil. 16, 148–156 (2010).
Santonicola, A. et al. Prevalence of functional dyspepsia and its subgroups in patients with eating disorders. World J. Gastroenterol. 18, 4379–4385 (2012).
Futagami, S. et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am. J. Gastroenterol. 105, 1835–1842 (2010).
Talley, N. J. et al. Non-ulcer dyspepsia and duodenal eosinophilia: an adult endoscopic population-based case-control study. Clin. Gastroenterol. Hepatol. 5, 1175–1183 (2007).
Walker, M. M. et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment. Pharmacol. Ther. 29, 765–773 (2009).
Aggarwal, K. R. et al. Duodenal eosinophilia and early satiety in functional dyspepsia (FD): confirmation of a positive biomarker association for FD in an Australian cohort [abstract]. Gastroenterology 142, S170–S171 (2012).
Bafutto, M. et al. Duodenal eosinophilia: a link between functional dyspepsia and post-infective functional dyspepsia [abstract]? Gastroenterology 142, S171 (2012).
Oshima, T. et al. The G-protein β3 subunit 825 TT genotype is associated with epigastric pain syndrome-like dyspepsia. BMC Med. Genet. 11, 13 (2010).
Shimpuku, M. et al. G-protein β3 subunit 825CC genotype is associated with postprandial distress syndrome with impaired gastric emptying and with the feeling of hunger in Japanese. Neurogastroenterol. Motil. 23, 1073–1080 (2011).
Toyoshima, F. et al. Serotonin transporter gene polymorphism may be associated with functional dyspepsia in a Japanese population. BMC Med. Genet. 12, 88 (2011).
Arisawa, T. et al. Genetic polymorphisms of SCN10A are associated with functional dyspepsia in Japanese subjects. J. Gastroenterol. 48, 73–80 (2013).
Hsu, Y. C. et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J. Gastroenterol. 46, 183–190 (2011).
Xiao, Y. L. et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am. J. Gastroenterol. 105, 2626–2631 (2010).
Futagami, S. et al. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion 86, 114–121 (2012).
Tack, J. & Janssen, P. Acotiamide (Z-338, YM-443), a new drug for the treatment of functional dyspepsia. Expert Opin. Investig. Drugs 20, 701–712 (2011).
Tack, J. et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol. Motil. 21, 272–280 (2009).
Matsueda, K. et al. Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology 128, A467 (2005).
Tack, J. F. et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia. Gastroenterology 140, S805–S805 (2011).
Matsueda, K. et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia—100 mg t.i.d. is an optimal dosage. Neurogastroenterol. Motil. 22, 618–e173 (2010).
Matsueda, K., Hongo, M., Tack, J., Saito Y. & Kato, H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 61, 821–828 (2012).
Van Oudenhove, L. et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 57, 1666–1673 (2008).
Acknowledgements
J. Tack would like to acknowledge the support of a Methusalem grant from Leuven University.
Author information
Authors and Affiliations
Contributions
Both authors contributed equally to all aspects of this article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tack, J., Talley, N. Functional dyspepsia—symptoms, definitions and validity of the Rome III criteria. Nat Rev Gastroenterol Hepatol 10, 134–141 (2013). https://doi.org/10.1038/nrgastro.2013.14
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2013.14
- Springer Nature Limited
This article is cited by
-
Efficacy of Bifidobacterium animalis subsp. lactis BL-99 in the treatment of functional dyspepsia: a randomized placebo-controlled clinical trial
Nature Communications (2024)
-
Reconsideration of the Gastroparetic Syndrome
Current Gastroenterology Reports (2023)
-
Clinical Efficacy of Tandospirone on Functional Dyspepsia Patients with Anxiety: A Randomized, Placebo-Controlled Study
Digestive Diseases and Sciences (2023)
-
Diagnose und Behandlung der funktionellen Dyspepsie in der klinischen Praxis
Schweizer Gastroenterologie (2023)
-
Therapeutic massage/Tuina for treatment of functional dyspepsia: a systematic review and meta-analysis of randomized controlled trials
Quality of Life Research (2023)